iShares Nasdaq Biotechnology (IBB)

Add to Watchlists
Create an Alert
325.53 -2.47  -0.75% NASDAQ Jan 27, 4:01PM BATS Real time Currency in USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 6.958B USD assets under management. It has an expected distribution yield of 0.02%, a Forecasted PE Ratio of 22.93, and a Forecasted Price to Book Value of 7.477. The fund has a net expense ratio of 0.48%, turns over its positions 39.00% per year, and is traded on the NASDAQ.

IBB Key Info

Expense Ratio (7-31-14) 0.48%
Assets Under Management (1-16-15) 6.958B
30-Day Average Volume (1-26-15) 1.605M
Net Asset Value (1-23-15) 322.57
Discount or Premium to NAV (1-16-15) 0.03%
Turnover Ratio (3-31-14) 39.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.00% 0.00% 0.00%
Stock 99.88% 99.88% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.12% 0.12% 0.00%
As of Jan. 15, 2015

IBB Region Exposure

Americas 95.63%
North America 95.63%
Latin America 0.00%
Greater Europe 4.33%
United Kingdom 2.01%
Europe Developed 2.25%
Europe Emerging 0.00%
Africa/Middle East 0.07%
Greater Asia 0.04%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.04%
Market Classification
% Developed Markets 99.96%
% Emerging Markets 0.04%
As of Jan. 23, 2015
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Jan. 15, 2015

IBB Stock Market Capitalization

Giant 33.65%
Large 21.24%
Medium 23.29%
Small 12.68%
Micro 9.01%
As of Jan. 15, 2015
View More Holdings

IBB Top 10 Holdings

Name % Weight Price Chg %
Biogen Idec Inc 8.70% 358.23 -1.16%
Celgene Corp 8.20% 122.35 -1.43%
Gilead Sciences Inc 7.65% 105.09 -1.89%
Amgen Inc 7.24% 158.42 -0.82%
Regeneron Pharmaceuticals Inc 6.28% 416.03 -1.83%
Vertex Pharmaceuticals Inc 3.94% 123.65 -1.17%
Illumina Inc 3.73% 203.58 +0.94%
Alexion Pharmaceuticals Inc 3.49% 180.20 -1.40%
Mylan Inc 3.34% 56.30 -0.88%
Biomarin Pharmaceutical Inc 2.44% 99.58 +0.07%
As of Jan. 15, 2015
Get Quote for
Advertisement

IBB Basic Info

Style
Broad Asset Class Sector Equity
Broad Category Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2014
Last Prospectus Date 7/31/2014
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available RRSP No

IBB Manager Info

Name Tenure
Diane Hsiung 7.01 yrs
Greg Savage 7.01 yrs
Jennifer Hsui 2.42 yrs
Matthew Goff 1.27 yrs

IBB Risk Info

Beta 0.9333
30 Day Average Volatility 31.82%

IBB Fundamentals

Dividend Yield TTM (1-27-15) 0.02%
Weighted Average PE Ratio 33.19
Weighted Average Price to Sales Ratio 9.186
Weighted Average Price to Book Ratio 7.945
Weighted Median ROE 9.99%
Weighted Median ROA 1.69%
Forecasted Dividend Yield 0.18%
Forecasted PE Ratio 22.93
Forecasted Price to Sales Ratio 8.510
Forecasted Price to Book Ratio 7.477
Number of Holdings 152.00
As of Jan. 15, 2015

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 17.25%
Forecasted Book Value Growth 10.71%
Forecasted Cash Flow Growth 10.70%
Forecasted Earnings Growth 30.73%
Forecasted Revenue Growth 12.50%
As of Jan. 15, 2015

IBB Performance

  Returns Total Returns
1M 6.17% 6.17%
3M 12.73% 12.73%
6M 28.13% 28.16%
1Y 33.40% 33.43%
3Y 183.8% 183.8%
5Y 293.3% 293.5%
As of Jan. 23, 2015

IBB Flows

1M 454.08M
3M 823.39M
6M 683.11M
YTD 1.002B
1Y 1.002B
3Y 2.064B
5Y 1.654B
As of Dec. 31, 2014
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 14-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 14 Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.